Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
Ryan T Hurt,1–4 Manpreet S Mundi,3 Jon O Ebbert5 1Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA; 2Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA; 3Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, M...
Saved in:
Main Authors: | Hurt RT, Mundi MS, Ebbert JO |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2018
|
Subjects: | |
Online Access: | https://doaj.org/article/30bc9e7e93e84bcfac4840001f22ecfc |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Converging Relationships of Obesity and Hyperuricemia with Special Reference to Metabolic Disorders and Plausible Therapeutic Implications
by: Gong M, et al.
Published: (2020) -
Lorcaserin Inhibit Glucose-Stimulated Insulin Secretion and Calcium Influx in Murine Pancreatic Islets
by: Muhan Jing, et al.
Published: (2021) -
Lorcaserin for weight management
by: Taylor JR, et al.
Published: (2013) -
Off-label drugs for weight management
by: Hendricks EJ
Published: (2017) -
Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
by: Sweeting AN, et al.
Published: (2014)